Management Appointment

Physiomics PLC 14 February 2008 Physiomics plc ('Physiomics' or 'the Company') 14 February 2008 Appointment of Group Financial Controller and Company Secretary Physiomics plc is pleased to announce the appointment of Mr. Roger John Jones as Group Financial Controller and Company Secretary. Mr. Jones has for 30 years been a Fellow of the Association of Chartered Certified Accountants and has held a number of senior financial positions and key roles in biotechnology and pharmaceutical companies including Cambridge Antibody Technology, Onyvax, Archimedes Pharma, Angel Biotechnology and Provensis. Commenting on this announcement, Physiomics' Chairman, Dr Paul Harper, said: 'I am delighted that Roger has agreed to join the Company in these capacities. He brings a wide range of experience to Physiomics and his considerable experience in the biotech sector make him an especially valuable addition to the executive team. We have already worked together on a number of projects and I know first hand what he will be able to contribute to the financial, commercial and strategic management of the business.' For further information: Physiomics plc +44 (0)7747 842 446 Dr Paul Harper E-mail: drpaulharper@tiscali.co.uk Grant Thornton Corporate Finance +44 (0)20 7383 5100 Philip Secrett, Colin Aaronson About Physiomics plc Physiomics plc (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. As 80-90 per cent of all clinical drug candidates fail to reach the market, estimates1 show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million. Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating most important molecular events taking place during the human cell cycle and apoptosis processes. Physiomics developed SystemCell(R) technology, a multi-cellular environment software, which enables the simulation of population of 'virtual cells'. Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com SystemCell(R) is a registered trademark of Physiomics plc 1Tufts Centre Impact Report 2002 This information is provided by RNS The company news service from the London Stock Exchange